TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Click for best price
Market Expansion
Cell and Gene Therapy (CGT) logistics encompasses the specialized transportation, storage, and handling services required to preserve the viability and integrity of cellular and gene‑based medicinal products from manufacturing facilities to clinical or commercial endpoints.
Demand is driven by the rapid expansion of CAR‑T, gene‑editing, and autologous cell‑based treatments, while challenges such as cold‑chain complexity, regulatory variance across borders, and limited real‑time monitoring capabilities persist.
Looking ahead, investments in digital tracking, cryogenic packaging innovations, and strategic partnerships between biotech firms and logistics providers are expected to mitigate risks and capture the projected 12% CAGR through 2034.
The global Cell and Gene Therapy (CGT) Logistic market was valued at US$1.1 billion in 2025 and is projected to reach US$4.3 billion by 2034, at a CAGR of 14.5 % during the forecast period.
Expansion of Cell Therapy Clinical Pipelines Fuels Logistic Demand
More than 400 cell and gene therapy candidates are now in clinical development, with over 30 products receiving regulatory approvals worldwide. The surge in approved autologous therapies such as CAR‑T cells requires highly specialized temperature‑controlled transport, often within a 24‑hour window, to preserve cell viability. Logistics providers have therefore invested in validated cold‑chain containers capable of maintaining −150 °C for cryopreserved products, a capability that has become a prerequisite for market entry. This infrastructure expansion directly drives revenue growth for CGT logistics firms.
Regulatory Emphasis on Traceability and Chain‑of‑Custody
Regulators across North America, Europe, and Asia are tightening requirements for electronic monitoring of temperature, location, and handling events throughout the shipment lifecycle. Real‑time data logging and blockchain‑based traceability solutions are being mandated for high‑risk biologics, prompting logistics providers to adopt integrated digital platforms. The need for compliant traceability accelerates adoption of premium logistic services, expanding the overall market size.
➤ For example, the European Medicines Agency (EMA) now requires full electronic temperature records for all advanced therapy medicinal products (ATMPs) shipped within the EU.
In addition, strategic mergers among logistics specialists and biopharma companies are consolidating capabilities, further reinforcing market growth.
MARKET CHALLENGES
High Costs of Specialized Cold‑Chain Infrastructure Tends to Challenge Market Growth
Maintaining ultra‑low temperatures (-150 °C to -80 °C) demands expensive equipment, validated packaging, and continuous monitoring. For small‑batch autologous therapies, the per‑shipment cost can exceed US$10,000, limiting accessibility in price‑sensitive regions. Capital‑intensive investments in dry‑ice logistics and proprietary containers therefore act as a barrier to entry for new service providers.
Other Challenges
Regulatory Hurdles
Stringent standards for sterility, temperature excursion limits, and customs clearance for biologics increase operational complexity. Navigating divergent regulations across 120+ countries often requires dedicated compliance teams, inflating overhead costs.
Ethical Concerns
The transport of genetically modified cells raises biosecurity questions, especially when shipments cross international borders. Concerns over accidental exposure or mishandling can lead to stricter import controls, adding further delays and costs.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
Delivering viable cell products requires precise thaw‑in‑transit protocols and rapid post‑shipment processing. Off‑target temperature excursions can reduce cell potency by up to 30 %, creating safety concerns and potential regulatory setbacks. Moreover, the rapid expansion of CGT manufacturing has outpaced the availability of trained logistics coordinators proficient in handling aseptic, temperature‑sensitive biologics. This talent gap hampers the ability of providers to scale operations efficiently.
Designing robust container validation studies, scaling production while ensuring batch‑to‑batch consistency, and recruiting specialized cold‑chain engineers are all critical challenges that limit the pace of market expansion.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Investment in next‑generation cryogenic packaging, such as vapor‑phase liquid nitrogen shippers, is creating new revenue streams. Leading logistics firms are forging alliances with cell processing centers to offer end‑to‑end solutions that include collection, processing, and delivery. These integrated models reduce hand‑offs, improve turnaround times, and attract premium contracts from biotech sponsors.
Additionally, regulatory agencies are issuing guidance that encourages the adoption of validated digital tracking platforms, opening avenues for technology providers to commercialize advanced monitoring services that command higher margins.
National Transportation Segment Dominates the Market Due to Critical Time‑Sensitive Cold‑Chain Requirements
The market is segmented based on type into:
National Transportation
International Transportation
Specialty Cryogenic Services
Regulatory & Compliance Solutions
Other Value‑Added Services
Biotech and Pharmaceutical Companies Segment Leads Owing to Extensive CGT Product Pipelines
The market is segmented based on application into:
Biotech and Pharmaceutical Companies
Hospitals and Clinical Centers
Research Organizations
Contract Manufacturing Organizations (CMOs)
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The global Cell and Gene Therapy (CGT) Logistic market was valued at US$ 2.6 billion in 2025 and is projected to reach US$ 5.4 billion by 2034, at a CAGR of 9.2% during the forecast period. The competitive landscape of the market is semi-consolidated, with large, medium, and small-size players operating in the market. Thermo Fisher Scientific Inc. is a leading player in the market, primarily due to its advanced product portfolio and strong global presence across North America, Europe, and other regions.
Takara Bio Inc. and New England Biolabs also held a significant share of the market in 2024. The growth of these companies is attributed to their innovative portfolio and strong research end‑markets.
Additionally, these companies' growth initiatives, geographical expansions, and new product launches are expected to grow the market share significantly over the projected period.
Meanwhile, Merck KGaA and Promega Corporation are strengthening their market presence through significant investments in R&D, strategic partnerships, and innovative product expansions, ensuring continued growth in the competitive landscape.
Thermo Fisher Scientific Inc.
Bio‑Rad Laboratories, Inc.
Fortis Life Sciences, LLC.
BioCat GmbH
Takara Bio Inc.
Danaher Corporation
The global Cell and Gene Therapy (CGT) Logistic market was valued at US$2.9 billion in 2025 and is projected to reach US$9.5 billion by 2034, at a CAGR of 14.7 % during the forecast period. A surge in late‑stage clinical trials and the regulatory approval of CAR‑T and CRISPR‑based products have heightened the need for ultra‑low‑temperature (ULT) storage and rapid, temperature‑controlled transportation. Cutting‑edge cold‑chain technologies such as vapor‑phase liquid nitrogen containers, active‑cooling dry shippers, and IoT‑enabled temperature‑monitoring platforms are now standard for preserving cell viability beyond 72 hours. In parallel, AI‑driven route optimization and blockchain‑based traceability are reducing transit times by up to 20 % while ensuring compliance with the stringent customs and biosafety requirements of international shipments. These logistics innovations are directly supporting the forecasted growth of the National Transportation segment, expected to reach US$4.1 billion by 2034, with a CAGR of 13 % over the next six years.
Personalized Medicine
Personalized cell and gene therapies, tailored to individual patient genetics, are expanding the logistics footprint across both national and cross‑border networks. Because each therapeutic dose is often patient‑specific and produced in limited batches, the industry now requires “just‑in‑time” delivery windows typically within 12 to 24 hours from manufacture to infusion. This urgency has spurred investment in dedicated courier fleets and regional cryogenic hubs, especially in the United States (estimated US$1.2 billion market size in 2025) and China (projected US$0.6 billion in 2025). Moreover, the rise of decentralized manufacturing sites is prompting on‑demand cold‑chain capacity sharing, allowing smaller biotech firms to access the same logistics infrastructure that once served only large multinational players. Collectively, these dynamics are driving the top five global logistics providers Cencora, World Courier, QuickStat, Associated Couriers, LLC, and Central Pharma to capture roughly 45 % of total market revenue in 2025.
Intensified R&D activities across biotech and pharmaceutical companies are accelerating the pipeline of novel CGT products, thereby expanding the demand for specialized logistics services. More than 300 cell‑based therapies are currently in Phase I/II trials, many of which require strict cryopreservation at – 150 °C and real‑time monitoring of metabolic parameters during transport. This research surge is prompting logistics firms to develop modular, GMP‑compliant cold‑storage units that can be rapidly deployed in emerging markets such as Southeast Asia and Latin America. Collaborative initiatives often funded by public‑private partnerships are also fostering the creation of regional “cold‑chain corridors” that link major manufacturing hubs in the United States, Europe, and Asia with clinical sites worldwide. As a result, international transportation is expected to grow at a comparable pace to national services, reinforcing the overall market trajectory toward a robust, globally integrated logistics ecosystem.
North America continues to dominate the global CGT Logistics market, representing roughly 38 % of total revenue in 2025. The United States alone accounts for more than half of the regional share, driven by the concentration of leading biotech hubs in Boston, San Francisco and the Research Triangle, as well as the presence of major logistics providers such as Cencora, Cardinal Health and Cryoport that have invested heavily in temperature‑controlled, time‑critical transportation networks. High‑value autologous therapies, especially CAR‑T and gene‑editing products, require ultralow‑temperature storage (‑80 °C to ‑196 °C) and same‑day delivery, prompting hospitals and contract manufacturing organizations to partner with specialist carriers that can guarantee FDA‑compliant cold‑chain integrity. In addition, the U.S. Food and Drug Administration’s recent guidance on real‑time temperature monitoring and the widespread adoption of electronic batch records have accelerated the uptake of digital traceability solutions, further cementing the region’s leadership. Canada and Mexico, while smaller, are benefitting from cross‑border agreements that allow seamless customs clearance for biologics, expanding the overall North American footprint. The region’s sustained capital expenditures approximately $3.5 billion in 2024 on advanced warehousing and last‑mile delivery underscore the maturity of the ecosystem and explain why North America retains the largest share of CGT logistics revenue worldwide.
Key Highlights:
Asia‑Pacific is expected to emerge as the fastest‑growing market for CGT logistics, posting a compound annual growth rate of roughly 12 % between 2026 and 2034. The surge is anchored by China’s rapid expansion of cell‑therapy manufacturing capacity, where more than 30 % of global CAR‑T production capacity will be located by 2028. Concurrently, India’s biotech sector is scaling up gene‑editing platforms, attracting multinational logistics firms to establish dedicated regional hubs in Singapore, Hong Kong and Shanghai. Government‑backed initiatives such as China’s “Made in 2025” and India’s “National Biopharma Mission” have paved the way for streamlined customs procedures, allowing biologics to cross borders within 24 hours under an “expedited biologics corridor.” Moreover, the proliferation of smart hospitals equipped with on‑site cryogenic storage has increased domestic demand for intra‑country transport, while international shipments are growing thanks to Asia‑Pacific firms seeking FDA‑approved markets. Investments exceeding $2 billion in the region’s cold‑chain infrastructure particularly in automated, robotic‑guided warehouses are expected to double storage capacity by 2030, reinforcing the projected acceleration.
Key Highlights:
How is the evolving regulatory landscape influencing regional demand for CGT Logistics?
The tightening of regulatory standards across major markets is reshaping demand patterns for CGT logistics services. In Europe, the European Medicines Agency’s (EMA) new Annex 1 guidelines on the manufacture of advanced therapy medicinal products (ATMPs) mandate real‑time temperature data logging and stringent deviation management, compelling logistics providers to integrate blockchain‑based traceability into every shipment. This regulatory pressure is stimulating growth in the European segment, where the market is expected to expand at a 9 % CAGR through 2034. Meanwhile, the United States’ recent revision of the “Biologics License Application” (BLA) requirements emphasizes validated cold‑chain processes and rapid release testing, prompting U.S. carriers to invest in AI‑driven predictive analytics that anticipate temperature excursions before they occur. In contrast, emerging markets in Latin America are still harmonizing their regulatory frameworks, resulting in slower adoption of high‑cost ultralow‑temperature solutions; however, pilot programs in Brazil and Argentina are introducing tiered compliance models that could unlock a 6 % regional growth rate. Overall, the global push toward tighter quality and safety standards is driving logistics firms to upgrade their infrastructure, creating a clear competitive advantage for providers that can demonstrably meet these evolving requirements.
Key Highlights:
Beyond the traditional powerhouses, several countries are fast becoming focal points for CGT logistics investment. In the United Kingdom, the government’s “Life Sciences Vision” program has allocated £200 million to develop a national cold‑chain network that links Oxford’s gene‑therapy research centers with London‑based manufacturing sites. Germany is leveraging its Mittelstand expertise to build modular, mobile cryogenic units that can be deployed to rural hospitals, positioning the country as a leader in decentralized CGT delivery. In the Middle East, the United Arab Emirates has launched a “Health‑Tech Free Zone” in Dubai, attracting global logistics firms with tax incentives and expedited customs for biologics, while Saudi Arabia’s Vision 2030 includes a dedicated $500 million fund for advanced therapy logistics infrastructure. Australia’s “Therapeutic Manufacturing Hubs” initiative offers grants for the establishment of ‑196 °C storage facilities along the East Coast, enabling rapid distribution to Oceania’s dispersed population. Collectively, these emerging hubs are expected to capture roughly 12 % of global CGT logistics revenue by 2034, driven by supportive policy environments, strategic public‑private partnerships, and a growing pipeline of locally developed cell and gene therapies.
The convergence of advanced manufacturing technologies and personalized medicine is a decisive catalyst for regional CGT logistics expansion. In North America, the rise of automated, closed‑system bioreactors has shortened production cycles for autologous therapies, creating a need for “just‑in‑time” logistics that can move a patient‑specific product from manufacturing to bedside within a 24‑hour window. This has spurred major carriers to launch dedicated “fast‑track” lanes equipped with real‑time GPS temperature monitoring and automated customs documentation. In Europe, the EU’s “Advanced Therapies Access Programme” incentivizes the establishment of regional GMP‑compliant manufacturing clusters, prompting logistics firms to co‑locate with these hubs to reduce cross‑border transit times. Asia‑Pacific’s rapid adoption of digital twins for supply‑chain modeling enables predictive capacity planning, allowing carriers to dynamically allocate ultra‑low‑temperature containers based on projected therapy demand. Meanwhile, Latin America’s emerging cell‑therapy clinics are partnering with multinational logistics providers to gain access to global cold‑chain expertise, thereby accelerating the region’s entry into the personalized medicine arena. Across all regions, the shift toward patient‑specific treatments is prompting a re‑evaluation of traditional hub‑spoke distribution models, favoring more agile, data‑driven networks that can guarantee product viability from manufacture to administration.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Cencora (formerly AmerisourceBergen), World Courier, QuickStat, Associated Couriers, LLC, Central Pharma, POLAR EXPRES, Biocair, time:matters, Mercury Business Services, Cardinal Health, CRYOPDP, Cryoport, NMDP BioTherapies, McKesson, Excel Courier, Almac, BEAM Logistics.
-> Key growth drivers include rapid increase in FDA‑approved cell and gene therapies, stringent cold‑chain requirements, rising demand for personalized medicine, and expanding global clinical trial networks.
-> North America remains the dominant region, accounting for roughly 45 % of 2025 revenue, while Asia‑Pacific is the fastest‑growing region with a CAGR above 12 % driven by China and Japan.
-> Emerging trends include AI‑driven temperature monitoring, blockchain‑based traceability, automated packaging solutions, and the development of decentralized, point‑of‑care manufacturing hubs, all aimed at reducing transit time and ensuring product integrity.
| Report Attributes | Report Details |
|---|---|
| Report Title | Cell and Gene Therapy (CGT) Logistic Market - AI Innovation, Industry Adoption and Global Forecast 2026-2034 |
| Historical Year | 2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year | 2025 |
| Forecast Year | 2033 |
| Number of Pages | 126 Pages |
| Customization Available | Yes, the report can be customized as per your need. |
Frequently Asked Questions
